Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab study in multiple myeloma as monotherapy and combination therapy
2022-501941-63-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2 trial of belantamab in multiple myeloma (MM) (2 arms), sponsored by GSK. Planned start Dec 2023; status: authorised.
02
Drugs
belantamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-501941-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501941-63-00.